Pathos AI Inc. announced that it has entered into a worldwide license agreement to develop FT-7051, a small molecule CBP/p300 inhibitor program from Novo Nordisk as Pathos' first clinical-stage asset in its pipeline. The development of this molecule reflects Pathos' commitment to precision medicine and biomarker-driven approaches in cancer treatment. The license will enable Pathos to continue the development of the drug and bring it to market as quickly and as safely as possible.

Pathos has not yet shared specific plans for P-300 but will disclose more details during upcoming oncology conferences.